AI via FreepikSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
EIBFab’entech, a French biopharma company, has secured a loan worth €20m from the European Investment Bank (EIB) under the HERA Invest programme, aimed at bolstering Europe’s preparedness against biological threats.
Kurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.
https://doi.org/10.3390/ijms241411791Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.
Spima TherapeuticsSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
GourmeyThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority when recommending novel food products for market authorisation.
Ovid Therapeutics - Jeremy LevinBy Jeremy Levin, D.Phil, MB BChir
Asabys PartnersAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
SR-TigitItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
Image by freepikAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.